Bioventus Lowers 2022 Guidance, Pauses M&A

Bioventus reported 3Q22 orthopedic revenue of $115.8 million, +20.5% compared to the third quarter of 2021.

The company lowered its 2022 guidance by $25.5 million, to a revised range of $527 million to $532 million. Reimbursement changes to hyaluronic acid (HA) therapies combined with salesforce realignment and supply chain issues in its...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us